Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

BACKGROUND: Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS) symptoms. However, it was deemed important to assess “clinically meaningful improvements, focusing on the patient’s chief complaint and the severity of major IBS symptoms” in addition to gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ida, Motoko, Nishida, Akito, Akiho, Hiraku, Nakashima, Yoshihiro, Matsueda, Kei, Fukudo, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356323/
https://www.ncbi.nlm.nih.gov/pubmed/28331539
http://dx.doi.org/10.1186/s13030-017-0093-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356323/
https://www.ncbi.nlm.nih.gov/pubmed/28331539
http://dx.doi.org/10.1186/s13030-017-0093-9

Ejemplares similares